Dostarlimab for treating primary advanced or recurrent endometrial cancer

Published on 13 Sep 2024
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Dostarlimab 500 mg concentrate for solution for infusion in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated mismatch repair deficient or microsatellite instability-high primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.

Funding status

Dostarlimab 500 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2025.

MAF assistance does not apply to untreated mismatch repair proficient or microsatellite stable primary advanced or recurrent endometrial cancer.

Clinical indications, subsidy class and MediShield Life claim limit for dostarlimab are provided in the Annex.

Dostarlimab for treating primary advanced or recurrent endometrial cancer (Updated 16 Sep 2025) [PDF, 236 KB]

PES Dostarlimab for treating primary advanced or recurrent endometrial cancer (Updated 16 Sep 2025) [PDF, 62 KB]